Sudan waxa uu wajahaya xaalad bani'aadamnimo oo sii xoogeysanaysa, taasoo si joogto ah u soo ifbaxaysa indhaha dunida. Mid ka mid ah waxyaabaha ugu xanuunka badan ee la ogaaday waa isticmaalka hubka kiimikada ee ciidamada Suudaan ay ku isticmaaleen dadka rayidka ah, taasoo ah xadgudub weyn oo ka dhan ah xuquuqda aadanaha, isla markaana ay si weyn uga hadleen ururada caalamiga ah iyo warbaahinta. Maqaalkii ugu dambeeyay ee The New York Times ayaa iftiimiyay xanuunka, isagoo muujinaya xaqiiqada nolosha ee hoos timaadda hoggaaminta Abdel Fattah Burhan, oo ah madaxda golaha militari ee Suudaan, iyo Ahmed Abdullah, oo mas'uul ka ah warshadaha militari ee Suudaan. Hubka Kiimikada iyo Xasuuqii Wad Madani Hubka kiimikada ayaa caan ku ah awoodda uu u leeyahay inuu si aan kala sooc lahayn ugu faafiyo waxyeello ba'an, taasoo saameyn weyn ku yeelan karta caafimaadka bini'aadamka. Isticmaalka hubka kiimikada ee ciidamada Suudaan ayaa ah xadgudub cad oo ka dhan ah sharciga caalamig...
.png)
In a groundbreaking move, Libya's Department of Support and Development of Medical Services (DSDMS) has announced a pivotal partnership with the UAE to provide advanced gene therapy treatment for children suffering from spinal muscular atrophy (SMA). This initiative represents a significant milestone in Libya’s healthcare system, reflecting its commitment to improving the quality of life for patients with rare and debilitating diseases.
Details of the Agreement
Ahmed Mlitan, head of the DSDMS, signed a contract with the UAE’s Jalila Children’s Hospital, renowned for its expertise in pediatric care and cutting-edge medical treatments. The agreement focuses on delivering gene therapy injections to 17 Libyan children diagnosed with SMA, a genetic condition that affects muscle strength and movement.
The initiative is a direct result of Prime Minister Abdel Hamid Aldabaiba’s decision No. 649 of 2024 and is being closely monitored by Libya’s Attorney General’s Office. According to the DSDMS, the move adheres to recommendations made by specialized scientific committees tasked with evaluating SMA treatments.
A Lifeline for SMA Patients
Spinal muscular atrophy is a rare genetic disorder characterized by the loss of motor neurons, which leads to muscle weakness and atrophy. Without treatment, the disease can severely impact mobility and quality of life. Gene therapy offers a revolutionary solution by addressing the underlying genetic cause of SMA, potentially halting disease progression and improving patient outcomes.
By providing access to this treatment, Libya is ensuring that affected children receive world-class medical care, setting a precedent for tackling rare diseases within the country.
Collaboration Beyond Borders
This partnership underscores the importance of international collaboration in advancing healthcare, particularly for nations striving to enhance their medical infrastructure. The UAE’s support through its Jalila Children’s Hospital demonstrates a shared commitment to humanitarian initiatives and the pursuit of innovative solutions for global health challenges.
A Hopeful Future
The provision of gene therapy marks a hopeful turning point for SMA patients and their families in Libya. It signifies not just a commitment to better healthcare but also an acknowledgment of the right to a healthier and more dignified life for those battling rare diseases.
As the initiative unfolds, it will likely inspire further advancements in Libya’s healthcare sector, paving the way for more partnerships and improved treatment accessibility.
This collaboration highlights how shared efforts can transform lives and serves as a testament to the power of science and compassion in addressing even the most complex medical challenges.
Posts
Comments
Post a Comment